Atezo+Bev study for pretreated patients

Phase II study of atezolizumab and bevacizumab combination therapy for the patients with advanced hepatocellular carcinoma previously treated with systemic chemotherapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041200068

Enrollment

Registered

2020-11-25

Start date

2020-11-26

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma hepatocellular carcinoma

Interventions

Atezolizumab and bevacizumab combination therapy

Atezolizumab and bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent

Exclusion criteria

Exclusion criteria: refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall survival, 6-month progression-free survival rate, 1year survival rate, Time to progression, Objective response rate, Tumor control rate, Subsequent therapy, Relative dose intensity, Adverse events	—

Contacts

Public ContactTakeshi Terashima

Kanazawa University Hospital

tera@m-kanazawa.jp+81-76-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 7, 2026